Sign inSubscribe

target directory

aln xdh placebo clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT05256810
Source recordAI-normalized

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout

The purpose of this study is to: * Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants * Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in adult patients with gout * Part C: Evaluate the safety, tolerability and efficacy of ALN-XDH as add-on therapy in adult patients with gout

AI analysis

Indication: Gout

Modality: small molecule

Target: ALN-XDH, Placebo

Sponsor: Alnylam Pharmaceuticals

Source URL: ClinicalTrials.gov

Source updated: Mar 29, 2024

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: ALN-XDH, Placebo

View original source fields

Condition raw: Gout

Condition normalized: Gout

Modality raw: small molecule

Modality normalized: small molecule

Target raw: ALN-XDH, Placebo

Target normalized: ALN-XDH, Placebo

Open report